Dicycloverinum [Inn-Latin] en es it fr

Dicycloverinum [Inn-Latin] Brand names, Dicycloverinum [Inn-Latin] Analogs

Dicycloverinum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Dicycloverinum [Inn-Latin] Chemical_Formula

C19H35NO2

Dicycloverinum [Inn-Latin] RX_link

http://www.rxlist.com/cgi/generic/dicyc.htm

Dicycloverinum [Inn-Latin] fda sheet

Dicycloverinum_[Inn-Latin] FDA

Dicycloverinum [Inn-Latin] msds (material safety sheet)

Dicycloverinum [Inn-Latin] Synthesis Reference

No information avaliable

Dicycloverinum [Inn-Latin] Molecular Weight

309.487 g/mol

Dicycloverinum [Inn-Latin] Melting Point

No information avaliable

Dicycloverinum [Inn-Latin] H2O Solubility

No information avaliable

Dicycloverinum [Inn-Latin] State

Solid

Dicycloverinum [Inn-Latin] LogP

5.476

Dicycloverinum [Inn-Latin] Dosage Forms

Capsule

Dicycloverinum [Inn-Latin] Indication

For the treatment of functional bowel/irritable bowel syndrome

Dicycloverinum [Inn-Latin] Pharmacology

Dicyclomine is an anticholinergic drug, a medication that reduces the effect of acetylcholine, a chemical released from nerves that stimulates muscles, by blocking the receptors for acetylcholine on smooth muscle (a type of muscle). It also has a direct relaxing effect on smooth muscle. Dicyclomine is used to treat or prevent spasm in the muscles of the gastrointestinal tract in the irritable bowel syndrome. In addition, Dicyclomine inhibits gastrointestinal propulsive motility and decreases gastric acid secretion and controls excessive pharyngeal, tracheal and bronchial secretions.

Dicycloverinum [Inn-Latin] Absorption

No information avaliable

Dicycloverinum [Inn-Latin] side effects and Toxicity

No information avaliable

Dicycloverinum [Inn-Latin] Patient Information

Dicyclomine may produce drowsiness or blurred vision. The patient should be warned not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery or to perform hazardous work while taking this drug.

Dicyclomine is contraindicated in infants less than 6 months of age and in nursing mothers. .

In the presence of a high environmental temperature, heat prostration can occur with drug use (fever and heat stroke due to decreased sweating).

If symptoms occur the drug should be discontinued and a physician contacted.

Dicycloverinum [Inn-Latin] Organisms Affected

Humans and other mammals